Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp50453_8k.htm |
Exhibit 99.1
|
Press Release
|
 |
|
www.shire.com
|
Director/PDMR Share Dealings
October 24, 2014 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces it was notified today that Flemming Ornskov, MD, Chief Executive Officer of the Company, acquired 15,500 ordinary shares of 5 pence each in the Company (“Shares”) today at an average price of £40.42 per share. The transaction took place on the London Stock Exchange.
Following the above transaction, Dr Ornskov holds 37,500 Shares. He also holds awards of Stock Appreciation Rights, Performance Shares and Deferred Shares over 187,401 ADSs. One ADS is equal to three Shares.
This notification is to satisfy the Company’s obligations under 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.
Tony Guthrie
Deputy Company Secretary
For further information please contact:
|
Investor Relations
|
||
|
Jeff Poulton
|
jpoulton@shire.com
|
+1 781 482 0945
|
|
Sarah Elton-Farr
|
seltonfarr@shire.com
|
+44 1256 894157
|
|
Media
|
||
|
Stephanie Fagan
|
sfagan@shire.com
|
+1 781 482 0460
|
|
Gwen Fisher
|
gfisher@shire.com
|
+1 484 595 9836
|
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.
www.shire.com
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX